202 related articles for article (PubMed ID: 33608980)
21. Chromatin-regulatory genes served as potential therapeutic targets for patients with urothelial bladder carcinoma.
Qiu JG; Shi DY; Liu X; Zheng XX; Wang L; Li Q
J Cell Physiol; 2019 May; 234(5):6976-6982. PubMed ID: 30317582
[TBL] [Abstract][Full Text] [Related]
22. Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
Wu Z; Wang M; Liu Q; Liu Y; Zhu K; Chen L; Guo H; Li Y; Shi B
Int J Med Sci; 2020; 17(1):89-96. PubMed ID: 31929742
[TBL] [Abstract][Full Text] [Related]
23. An outcome model for human bladder cancer: A comprehensive study based on weighted gene co-expression network analysis.
Xiong Y; Yuan L; Xiong J; Xu H; Luo Y; Wang G; Ju L; Xiao Y; Wang X
J Cell Mol Med; 2020 Feb; 24(3):2342-2355. PubMed ID: 31883309
[TBL] [Abstract][Full Text] [Related]
24. Extracellular matrix-related genes play an important role in the progression of NMIBC to MIBC: a bioinformatics analysis study.
Zhang H; Shan G; Song J; Tian Y; An LY; Ban Y; Luo GH
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32391563
[TBL] [Abstract][Full Text] [Related]
25. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
26. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.
Erill N; Colomer A; Verdú M; Román R; Condom E; Hannaoui N; Banús JM; Cordon-Cardo C; Puig X
Diagn Mol Pathol; 2004 Dec; 13(4):217-23. PubMed ID: 15538112
[TBL] [Abstract][Full Text] [Related]
27. [Construction of prognostic model and identification of prognostic biomarkers based on the expression of long non-coding RNA in bladder cancer via bioinformatics].
Yang FL; Hong K; Zhao GJ; Liu C; Song YM; Ma LL
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Aug; 51(4):615-622. PubMed ID: 31420610
[TBL] [Abstract][Full Text] [Related]
28. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
29. Identification of prognostic biomarkers associated with stromal cell infiltration in muscle-invasive bladder cancer by bioinformatics analyses.
Li P; Cao J; Li J; Yao Z; Han D; Ying L; Wang Z; Tian J
Cancer Med; 2020 Oct; 9(19):7253-7267. PubMed ID: 32786144
[TBL] [Abstract][Full Text] [Related]
30. Tumor‑infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer.
Xue Y; Tong L; LiuAnwei Liu F; Liu A; Zeng S; Xiong Q; Yang Z; He X; Sun Y; Xu C
Oncol Rep; 2019 Aug; 42(2):581-594. PubMed ID: 31233191
[TBL] [Abstract][Full Text] [Related]
31. Genome-wide screening of abberant methylated drivers combined with relative risk loci in bladder cancer.
Zhang C; Shen K; Zheng Y; Qi F; Luo J
Cancer Med; 2020 Jan; 9(2):768-782. PubMed ID: 31794632
[TBL] [Abstract][Full Text] [Related]
32. Identification of biomarkers associated with progression and prognosis in bladder cancer via co-expression analysis.
Shi S; Tian B
Cancer Biomark; 2019; 24(2):183-193. PubMed ID: 30689556
[TBL] [Abstract][Full Text] [Related]
33. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma.
Zhang C; Shen L; Qi F; Wang J; Luo J
J Cell Physiol; 2020 Apr; 235(4):3849-3863. PubMed ID: 31596511
[TBL] [Abstract][Full Text] [Related]
34. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.
Sanford T; Meng MV; Railkar R; Agarwal PK; Porten SP
Clin Epigenetics; 2018; 10():19. PubMed ID: 29456764
[TBL] [Abstract][Full Text] [Related]
35. Exploring the FGFR3-related oncogenic mechanism in bladder cancer using bioinformatics strategy.
Cao W; Ma E; Zhou L; Yuan T; Zhang C
World J Surg Oncol; 2017 Mar; 15(1):66. PubMed ID: 28320388
[TBL] [Abstract][Full Text] [Related]
36. Bioinformatics Analysis of the Expression of Key Long Intergenic Non-Protein Coding RNA Genes in Bladder Cancer.
Lin YZ; Wu YP; Ke ZB; Cai H; Chen DN; Chen SH; Li XD; Lin TT; Huang JB; Zheng QS; Xue XY; Xu N; Wei Y
Med Sci Monit; 2020 Apr; 26():e920504. PubMed ID: 32277695
[TBL] [Abstract][Full Text] [Related]
37. Molecular network-based identification of competing endogenous RNAs in bladder cancer.
Jiang WD; Yuan PC
PLoS One; 2019; 14(8):e0220118. PubMed ID: 31369587
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of PD-L1 in bladder cancer.
Huang Y; Zhang SD; McCrudden C; Chan KW; Lin Y; Kwok HF
Oncol Rep; 2015 Jun; 33(6):3075-84. PubMed ID: 25963805
[TBL] [Abstract][Full Text] [Related]
39. Identifying the mRNAs associated with Bladder cancer recurrence.
Cao H; Cheng L; Yu J; Zhang Z; Luo Z; Chen D
Cancer Biomark; 2020; 28(4):429-437. PubMed ID: 32390597
[TBL] [Abstract][Full Text] [Related]
40. Characterization of mRNA Expression and Endogenous RNA Profiles in Bladder Cancer Based on The Cancer Genome Atlas (TCGA) Database.
Xu Z; Wang C; Xiang X; Li J; Huang J
Med Sci Monit; 2019 Apr; 25():3041-3060. PubMed ID: 31020952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
